Retatrutide 6mg

Peptide Science research editorial team.

Retatrutide 6mg Overview

Retatrutide 6mg from Peptide Science is supplied as a lyophilised vial at 6 mg for in-vitro and preclinical adipose / metabolic research. Retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist characterised in preclinical work for receptor-binding affinity and downstream incretin- or amylin-pathway signalling in pancreatic and adipose-tissue cell culture.

Receptor Profile and Class Background

Retatrutide is a 39-amino-acid synthetic triple-agonist peptide engineered to bind the GLP-1 receptor, the GIP receptor, and the glucagon receptor simultaneously. The triple-receptor profile distinguishes it from the dual-agonist Tirzepatide (GLP-1 plus GIP) and the single-agonist Semaglutide (GLP-1 only). Research interest centres on the additional glucagon-receptor activity, which may increase basal energy expenditure in adipocyte cell-culture models alongside the incretin-pathway effects shared with the other class members. Browse the broader metabolic peptide research range for adjacent compounds.

Specifications

For higher-strength formats, see Retatrutide 12mg and Retatrutide 16mg.

Reconstitution and Handling

The lyophilised vial reconstitutes with bacteriostatic water at the working concentration set by the principal investigator. Material is sensitive to repeated freeze-thaw cycles; aliquoting reconstituted stock for single-use frozen storage is the standard preclinical handling practice cited in incretin-research literature.

Quality and Shipping

Each batch passes HPLC at greater than 99 percent purity, with mass-spectrometry identity confirmation against the theoretical mass. A Certificate of Analysis accompanies every order. Material is filled in a US laboratory under ISO 9001:2015-aligned quality systems and dispatched in temperature-monitored insulated packaging via overnight or two-day courier.

For laboratory research and development use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease, including obesity or type 2 diabetes. Has not been evaluated by the U.S. Food and Drug Administration. Branded therapeutic GLP-1, GIP, and dual-agonist medicines (Ozempic, Wegovy, Mounjaro, Zepbound) are prescription-only medicines in the United States and are not the same as research-grade compounds supplied for in-vitro work. Purchasers acknowledge they are qualified researchers age 21 or older and accept responsibility for compliance with all applicable federal, state, and local laws.